Johnson & Johnson Stock: Is JNJ Outperforming the Consumer Staples Sector?
Johnson & Johnson has outpaced the consumer staples sector over the past year, while analysts remain moderately bullish on the stock’s prospects.
New Brunswick, New Jersey-based Johnson & Johnson (JNJ) is a diversified global healthcare giant with operations spanning prescription medicines and medical technology. Valued at a market cap of $640.5 billion, the company operates through two core segments: Innovative Medicine and MedTech.
Companies with a market capitalization of $200 billion or more are typically referred to as "mega-cap stocks." JNJ fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the general drug manufacturers industry.
JNJ’s recent performance has been notably strong, with the stock just 3.1% below its 52-week high of $276.47, reached on Aug. 19. The rally has been particularly impressive over the shorter term, with JNJ up 16.1% over the past three months, outpacing the State Street Consumer Staples Select Sector SPDR Fund (XLP), which climbed 1.2%.
Over the past 52 weeks, JNJ has surged 52.8%, outperforming the ETF’s 6.5% rise. In 2026, the stock is up 29.5%, compared to XLP's 6.5% rally.
JNJ has also been trading above its 50-day and 200-day moving averages for most of the past year, indicating an uptrend.
Johnson & Johnson has outpaced the broader market as strong pharmaceutical growth, a resilient MedTech business and improving earnings expectations have renewed investor confidence.
On July 15, JNJ released its FY2026 Q2 earnings, and its shares rose 1.2% in the next trading session. The positive reaction reflected solid quarterly growth and an improved outlook, as J&J’s sales increased 6.6% year over year to $25.31 billion, driven by continued strength in its Innovative Medicine and MedTech businesses. Its adjusted EPS stood at $2.90, exceeding market expectations. The company also raised its full-year 2026 outlook, lifting its adjusted EPS guidance by $0.13 to $11.58 and projecting sales of $101.1 billion at the midpoint.
When stacked against its peer, Eli Lilly and Company (LLY), JNJ has underperformed. Over the past year, LLY stock has surged 60.5%.
Additionally, sentiment on JNJ remains moderately optimistic. Among the 24 analysts covering the stock, the consensus rating is a “Moderate Buy.” Its mean price target of $276.29 suggests a 3.1% upside potential from current price levels.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.